Elekta’s MR-linac featured in 21 abstracts at 2017 AAPM Annual Meeting
Elekta’s (EKTA-B.ST) transformative magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition. The meeting is taking place July 30 - August 3 in Denver.
Elekta’s MR-linac is the only MR/RT system that integrates a high-field (1.5 Tesla) MR scanner with an advanced linear accelerator and intelligently-designed software. The system is expected to deliver precisely-targeted radiation doses while simultaneously capturing the highest-quality MR images, which will allow clinicians to visualize tumors at any time and adapt the treatment accordingly. Elekta introduced the MR-linac technology under the name of Elekta Unity during the ESTRO congress in Vienna, Austria in April 2017.
Two abstracts that highlight the performance characteristics of MR-linac will be presented on Tuesday, August 1, 1:45 – 3:45 p.m. in a session on MR-guided radiation therapy.
This abstract reports the initial results of system level tests conducted on MR-linac by researchers at the Froedtert & Medical College of Wisconsin Clinical Cancer Center at Froedtert Hospital. The system successfully passed multiple tests assessing imaging and dosimetry performance and the study results also demonstrate successful delivery and measurement of an intensity modulated radiation therapy (IMRT) treatment plan. The data show that the integration of a linac and a high-field MRI does not compromise the performance of either system.
This abstract describes results of a study undertaken to determine the ability of Elekta’s MR-linac to perform real-time motion compensation. Researchers at University Medical Center Utrecht (UMCU) conducted the study, in which experimental software was used to investigate imaging and feedback performance. Results show that the time required to reconstruct and transport image data after acquisition was 62 milliseconds, and that overall time to gate the beam was 407.6 milliseconds, including the real-time image processing of 5 images per second. The authors conclude that these times are promising and support real-time applications of MR-linac, such as motion compensation.
“These data underscore that Elekta’s MR-linac system meets the critical objectives of accurately delivering a radiation dose while simultaneously capturing high-quality MR images,” said Allen Li, PhD, Medical College of Wisconsin Professor and Chief of Medical Physics at Froedtert Hospital and an author on the first abstract. “The successful delivery and measurement of an IMRT treatment plan is an important milestone in the development of Elekta’s MR-linac system, which has the potential to be a revolutionary technology for cancer care.”
Additional abstracts demonstrating the potential of Elekta’s MR-linac system to improve patient care, include:
This abstract describes how Elekta’s MR-linac improves dose volume parameters and reduces the exposure of organs at risk (OAR) compared with cone beam CT imaging in patients with lymph node oligometastases. Researchers at UMCU conducted the research and conclude that the high-field MRI guidance that Elekta’s MR-linac provides paves the way for further dose escalation and hypofractionation.
This abstract reports that treatment replanning for prostate cancer can be done in less than two minutes with Elekta’s MR-linac and shows that daily treatment replanning led to more consistent plans and ensured target coverage enabling OAR sparing via margin reduction. The research was conducted at UMCU.
This abstract highlights the use of Monaco®, Elekta’s proprietary treatment planning software system, in concert with its MR-linac. Results show that the presence of the 1.5T magnet did not affect the quality of the treatment plan, and that the treatment plan resulted in reduced exposure of the heart in a patient needing treatment in the esophagus. Researchers at the University of Texas MD Anderson Cancer Center conducted the research.
“The Elekta MR-linac Consortium continues to make excellent progress in validating the performance of MR-linac and highlighting the tremendous potential that this system has in transforming radiation therapy for the treatment of cancer,” said Kevin Brown, Elekta’s Global Vice President of Scientific Research. “UMCU treated the first patient with MR-linac in May and we expect that other consortium sites will initiate human trials over the next several months. These studies will provide important insight into how to leverage the power of MR-linac to optimize patient care and outcomes. We remain on track to submit for CE mark approval of MR-linac in the second half of 2017, followed with filing of FDA 510(k) in 2018.”
Geoffrey Ibbott, PhD, Deputy Division Head, Department of Radiation Physics, Cancer Network Integration – Medical Physics at the University of Texas MD Anderson Cancer Center, will also give a presentation titled “MRI/Linac” at 10:35 a.m. on Wednesday, August 2, in the Recent Advancement of Imaging Guidance in Clinical Trial session.
During his talk, Dr. Ibbott will discuss how a linear accelerator can be paired with a high-field 1.5 Tesla clinical magnet resonance imager to provide image-guided radiation therapy with superior soft-tissue image quality. The benefits of MR-guided radiation therapy will be addressed, and issues related to dosimetry that result from the presence of the magnetic field.
To learn more about Elekta’s MR-linac, visit Elekta booth 5047 at AAPM or www.elekta.com/Unity.
Elekta Unity is a work in progress and not available for sale or distribution.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: raven.canzeri@elekta.com
Time zone: EST: Eastern Standard Time
About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com